Sign in
CompletedPhase 1

Rifaximin in Patients With Monoclonal Gammopathy

Key facts

Who runs it
Emory University
Where
Atlanta, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
50 people enrolled
Started
15 May 2019
Ended
30 Nov 2025
Type of study
Interventional
Treatments tested
  • Rifaximin
Record updated
26 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • Clinical diagnosis of monoclonal gammopathy of undetermined significance based on International Myeloma Working Group (IMWG) criteria
  • Patients will be enrolled into one of 3 cohorts:; Cohort A: IgA gammopathy; Cohort B: IgG gammopathy / or light chain gammopathy; Cohort C: IgM gammopathy / asymptomatic macroglobulinemia
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Patients who have received antibiotics within last 3 weeks
  • Patients who are receiving any other investigational agents for gammopathy. Patients with clinical myeloma requiring anti-myeloma therapy are also excluded
  • The effects of rifaximin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of rifaximin administration
  • History of allergic reactions or intolerance attributed to rifaximin or compounds of similar chemical or biologic composition to antibiotic under study

Where in United States

  • Emory University Hospital/Winship Cancer InstituteAtlanta, United States

About the trial

What the trial wants to find out

This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

The group in the trial

  • Treatment (rifaximin)Treatment being tested

    Patients receive rifaximin PO TID on days 1-14 in the absence of disease progression or unacceptable toxicity.

    Treatment: Rifaximin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy
Record updated
26 May 2026